110 related articles for article (PubMed ID: 23763922)
21. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas.
Terhorst D; Mestel DS; Humme D; Sterry W; Beyer M
Br J Dermatol; 2012 Jun; 166(6):1295-300. PubMed ID: 22356095
[TBL] [Abstract][Full Text] [Related]
23. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
26. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
27. [Clinical analysis of childhood and adolescent Hodgkin's lymphoma: a report of 88 cases].
Xing PY; Shi YK; He XH; Zhou LQ; Dong M; Yang JL; Liu P
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):692-7. PubMed ID: 23159084
[TBL] [Abstract][Full Text] [Related]
28. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
29. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
30. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
[TBL] [Abstract][Full Text] [Related]
31. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
33. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study.
Hallermann C; Niermann C; Fischer RJ; Schulze HJ
Acta Derm Venereol; 2011 Sep; 91(5):521-5. PubMed ID: 21547335
[TBL] [Abstract][Full Text] [Related]
34. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Hong J; Yoon HH; Ahn HK; Sym SJ; Park J; Park PW; Ahn JY; Park S; Cho EK; Shin DB; Lee JH
Acta Haematol; 2013; 130(4):305-11. PubMed ID: 24008775
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
38. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers.
Senff NJ; Hoefnagel JJ; Jansen PM; Vermeer MH; van Baarlen J; Blokx WA; Canninga-van Dijk MR; Geerts ML; Hebeda KM; Kluin PM; Lam KH; Meijer CJ; Willemze R
J Clin Oncol; 2007 Apr; 25(12):1581-7. PubMed ID: 17353548
[TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
40. Treatment and outcomes of primary breast lymphoma.
Caon J; Wai ES; Hart J; Alexander C; Truong PT; Sehn LH; Connors JM
Clin Breast Cancer; 2012 Dec; 12(6):412-9. PubMed ID: 23018097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
